ArticleInvestigational new drugs2017

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.

Su Jin Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.